{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-018242","form_type":"8-K","ticker":"INBS","cik":"0001725430","company_name":"INTELLIGENT BIO SOLUTIONS INC.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.757999+00:00","generated_at":"2026-06-02T11:48:12.071088+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Intelligent Bio Solutions Q3 revenue up 80% to $0.82M; cash $9.4M after $10.76M capital raise","bullets":["Revenue of $0.82M for Q3 FY2024, up 80% YoY; nine-month revenue $2.38M, up 193%.","Net loss for Q3 was $2.98M, including $0.54M non-cash items; nine-month net loss decreased to $7.37M.","Cash and equivalents $9.4M as of March 31, 2024, up from $1.1M at Dec 31, 2023, after net capital raise of ~$10.76M.","FDA 510(k) clinical studies with Cliantha Research underway; submission expected by end of 2024, US entry planned in 2025.","Secured 26 new accounts during quarter, representing ~16,779 employees; European patent granted for DSR-Plus Cartridge Reader."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-018242","json":"https://secwatch.observer/filing/0001493152-24-018242.json","markdown":"https://secwatch.observer/filing/0001493152-24-018242.md","text":"https://secwatch.observer/filing/0001493152-24-018242.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725430/000149315224018242/0001493152-24-018242-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725430/000149315224018242/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T11:48:12.071088+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4f3cf9ca7196215546762cb1aebe3834d61497b2","claim":"INTELLIGENT BIO SOLUTIONS INC. reported nine months ended March 31, 2024 results: revenue $2.38 million, net income $7.37 million.","evidence_excerpt":"Total revenue for the nine months ended March 2024 was $2.38 million, an increase of 193% compared to the same period the year prior.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725430/000149315224018242/0001493152-24-018242-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"nine months ended March 31, 2024"},{"label":"Revenue","value":"$2.38 million"},{"label":"Net income","value":"$7.37 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"decfecf18253f053f2455a62a1435f867e7bf2d4","claim":"INTELLIGENT BIO SOLUTIONS INC. reported fiscal third quarter ended March 31, 2024 results: revenue $0.82 million, net income $2.98 million.","evidence_excerpt":"Total revenues for the fiscal third quarter were $0.82 million, an increase of 80% compared to the same period the year prior.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725430/000149315224018242/0001493152-24-018242-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal third quarter ended March 31, 2024"},{"label":"Revenue","value":"$0.82 million"},{"label":"Net income","value":"$2.98 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}